The Immunoadoptive Cell Therapy Private Limited (ImmunoACT), based in Mumbai, India, on October 13, 2023, announced the Central Drugs Standard Control Organization (CDSCO)’s approval for the use of the country’s first chimeric antigen receptor (CAR-T) cell therapy for the treating relapsed-refractory B-cell lymphoma and leukemia.
Trending
- WAF urges investment in food security
- NGO mobilises students for handwashing
- Kogi assesses climate finance readiness
- FAAC distributes ₦2.43tn to federal, state, local governments for September
- NSA seek more staff, better equipment
- Financial services drive Nigeria’s FX demand to highest level since 2011
- Nigeria’s $55.1bn reserves provide shield against global shocks — Cardoso
- IMF backs CBN’s 23% rate reset, says inflation progress justifies move
